Eli Lilly and Company $LLY Shares Acquired by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 20.8% during the third quarter, HoldingsChannel reports. The fund owned 5,743 shares of the company’s stock after buying an additional 989 shares during the period. Azzad Asset Management Inc. ADV’s holdings in Eli Lilly and Company were worth $4,382,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. First Dallas Securities Inc. increased its stake in Eli Lilly and Company by 33.8% during the third quarter. First Dallas Securities Inc. now owns 5,943 shares of the company’s stock worth $4,535,000 after acquiring an additional 1,500 shares during the last quarter. Cyr Financial Inc. grew its holdings in shares of Eli Lilly and Company by 3.0% during the 3rd quarter. Cyr Financial Inc. now owns 1,116 shares of the company’s stock worth $852,000 after purchasing an additional 33 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Eli Lilly and Company by 32.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 11,467 shares of the company’s stock worth $8,331,000 after purchasing an additional 2,820 shares during the last quarter. First National Bank of Hutchinson increased its position in shares of Eli Lilly and Company by 3.3% during the 3rd quarter. First National Bank of Hutchinson now owns 1,524 shares of the company’s stock worth $1,163,000 after purchasing an additional 48 shares during the last quarter. Finally, Chapman Investment Management LLC raised its holdings in Eli Lilly and Company by 12.9% in the 3rd quarter. Chapman Investment Management LLC now owns 3,486 shares of the company’s stock valued at $2,660,000 after buying an additional 397 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and stunning 2026 guidance — Lilly reported strong Q4 revenue and EPS and issued 2026 guidance well above Street expectations, which sparked the initial rally as investors priced in sustained GLP‑1 growth and margin leverage. Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut
• Positive Sentiment: Analysts raising price targets — Multiple banks (JPMorgan, Morgan Stanley, Cantor Fitzgerald) lifted LLY price targets and kept overweight/positive views after the results, supporting upside expectations. Price Target Raised to $1,300.00 at JPMorgan Chase & Co. Price Target Raised to $1,313.00 at Morgan Stanley Price Target Raised to $1,205.00 at Cantor Fitzgerald
• Positive Sentiment: Manufacturing and capacity expansion — Lilly is expanding GLP‑1 capacity and building greenfield sites to meet volume demand, which investors view as a durable competitive advantage versus peers constrained by supply. Eli Lilly Expands GLP-1 Capacity While Building Beyond Obesity And Diabetes
• Neutral Sentiment: Obesity market size and longer‑term thesis — Coverage highlights a very large addressable market (approaching ~$100B for obesity drugs), reinforcing the long‑term growth story even as short‑term skirmishes play out. Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn’t Ignore
• Neutral Sentiment: Fund/score coverage — Research pieces (Zacks, institutional letters) reinforce Lilly’s growth ranking and investor interest, but are confirmatory rather than catalytic. Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Competitive pricing pressure from compounded copies — Hims & Hers launching low‑cost compounded semaglutide pills ($49 introductory) triggered a selloff as investors feared erosion of pricing/patient share for branded oral options. This remains the main short‑term risk to LLY’s oral launch economics. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Regulatory/legal noise — Separately, securities‑law firms have flagged investigations into certain transactions and board conduct; these are reputational/legal items to monitor but not yet material to the core GLP‑1 thesis. Investor Alert: Scott+Scott Investigates Directors and Officers

Eli Lilly and Company Stock Up 3.6%

Eli Lilly and Company stock opened at $1,057.10 on Friday. The firm has a market capitalization of $999.37 billion, a P/E ratio of 46.06, a P/E/G ratio of 0.76 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock’s fifty day simple moving average is $1,052.25 and its 200-day simple moving average is $899.06.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business posted $5.32 earnings per share. Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Truist Financial set a $1,281.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Guggenheim lowered their price objective on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Bank of America cut their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. HSBC restated a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,203.75.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.